EA202091903A1 - CRYSTAL FORM OF BITEGAVIR-SODIUM - Google Patents

CRYSTAL FORM OF BITEGAVIR-SODIUM

Info

Publication number
EA202091903A1
EA202091903A1 EA202091903A EA202091903A EA202091903A1 EA 202091903 A1 EA202091903 A1 EA 202091903A1 EA 202091903 A EA202091903 A EA 202091903A EA 202091903 A EA202091903 A EA 202091903A EA 202091903 A1 EA202091903 A1 EA 202091903A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sodium
present
bitegavir
crystal form
bitegravir
Prior art date
Application number
EA202091903A
Other languages
Russian (ru)
Inventor
Ханнес Ленгауэр
Артур Пихлер
Ренате Марграйтер
Original Assignee
Сандоз Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сандоз Аг filed Critical Сандоз Аг
Priority claimed from PCT/EP2019/051818 external-priority patent/WO2019154634A1/en
Publication of EA202091903A1 publication Critical patent/EA202091903A1/en

Links

Abstract

Настоящее изобретение относится к кристаллической форме битегравир-натрия и к способу его получения. Кроме того, настоящее изобретение относится к фармацевтической композиции, включающей указанную кристаллическую форму битегравир-натрия, предпочтительно в заранее заданном и/или эффективном количестве, по меньшей мере один фармацевтически приемлемый инертный наполнитель и необязательно одно или более дополнительных противовирусных средств. Фармацевтическую композицию, предлагаемую в настоящем изобретении, можно использовать в качестве лекарственного средства, в частности, для лечения и/или профилактики инфекций HIV-1.The present invention relates to the crystalline form of bitegravir sodium and to a method for its preparation. In addition, the present invention relates to a pharmaceutical composition comprising said crystalline form of bitegravir sodium, preferably in a predetermined and / or effective amount, at least one pharmaceutically acceptable excipient and optionally one or more additional antiviral agents. The pharmaceutical composition of the present invention can be used as a medicine, in particular for the treatment and / or prevention of HIV-1 infections.

EA202091903A 2018-09-13 2019-01-25 CRYSTAL FORM OF BITEGAVIR-SODIUM EA202091903A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18194234 2018-09-13
PCT/EP2019/051818 WO2019154634A1 (en) 2018-02-09 2019-01-25 Crystalline form of bictegravir sodium

Publications (1)

Publication Number Publication Date
EA202091903A1 true EA202091903A1 (en) 2020-10-28

Family

ID=63579169

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091903A EA202091903A1 (en) 2018-09-13 2019-01-25 CRYSTAL FORM OF BITEGAVIR-SODIUM

Country Status (2)

Country Link
EA (1) EA202091903A1 (en)
PT (1) PT3749673T (en)

Also Published As

Publication number Publication date
PT3749673T (en) 2022-06-20

Similar Documents

Publication Publication Date Title
EA201892395A1 (en) DRUG COMPOSITIONS OF LSD1 INHIBITOR
EA201891103A1 (en) COMPOSITIONS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY
EA201890425A1 (en) ANTI-VIRUS PHOSPHODIAMIDE COMPOSITE BETA-AMINO ACID COMPOUNDS
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
ECSP19083621A (en) INDOLINE DERIVATIVES SUBSTITUTE AS INHIBITORS OF DENGUE VIRAL REPLICATION
EA201592250A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseases
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
EA202191239A1 (en) COMPOUNDS AND THEIR APPLICATION FOR TREATMENT OF 1-ANTITRIPSIN DEFICIENCY
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MY195194A (en) Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
BR112015013695A2 (en) pharmaceutical composition and methods for treating and preventing an HIV infection
EA201890654A1 (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF THE HUMAN IMMUNODEFICIENCY VIRUS
EA201691490A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING BRINZOLAMIDE
MX2020008360A (en) Crystalline form of bictegravir sodium.
MY170991A (en) Dosing regimens of celgosivir for the treatment of dengue
MX2021015441A (en) Crystalline forms of cabotegravir sodium.
EA202091903A1 (en) CRYSTAL FORM OF BITEGAVIR-SODIUM
AR108792A1 (en) COMPOSITIONS THAT INCLUDE TIMOLOL
MX2019015480A (en) Combined medicinal preparation for treating viral infections.
EA201992816A1 (en) PHARMACEUTICAL COMPOSITION AND MEDICINAL FORM THAT INCLUDES (E) -4- (2- (AMINOMETHYL) -3-FLOROLLYLOXY) -N-THR-BUTYLBENZAMIDE, METHOD FOR THEIR PREPARATION AND APPLICATION, APPLICATION
EA201991381A1 (en) Composition for the treatment of osteoarthritis
WO2014140680A8 (en) Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection
UA123399U (en) PHARMACEUTICAL COMPOSITION OF CHOLINE ALPHOSCERATE IN MEDICINAL FOR ORAL USE
EA201990656A1 (en) Pyrrolopyrimidine compounds used as a TLR7 agonist